Alcon Inc. remains a global leader in eye care, benefiting from aging demographics and technological innovation, but faces valuation and growth headwinds. Recent M&A activity, including the pending STAAR Surgical deal, pressures near-term earnings and adds uncertainty, despite strategic fit. ALC shares have declined from highs, now trading at a more reasonable 25 times earnings, but growth is slowing, and valuation remains somewhat elevated.
Alcon posts mixed Q3 results as earnings top estimates but revenues miss; new product launches fuel optimism.
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Evaluate the expected performance of Alcon (ALC) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Investors with an interest in Medical - Instruments stocks have likely encountered both Alcon (ALC) and Intuitive Surgical, Inc. (ISRG). But which of these two stocks offers value investors a better bang for their buck right now?
The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecutive quarter of double-digit revenue and profit growth. Japan was the largest detractor, with Chugai and Sysmex weighing on results.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
ALC's Q2 earnings top estimates but revenues fall short, sending shares down more than 10% as margins tightened and 2025 sales outlook narrowed.
Alcon Inc. (NYSE:ALC ) Q2 2025 Earnings Conference Call August 20, 2025 8:00 AM ET Call Participants Daniel Cravens - Vice President of Investor Relations David J. Endicott - CEO & Director Timothy C.
The company said it expects a $100 million hit from tariffs this year.
The headline numbers for Alcon (ALC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.